Introduction to Radon: Continuing Education Course

Radon Testing and Mitigation to Protect Health: Module 3

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • Other: 0.50
    • CPHCE: 0.50
    • CHES: 0.50
    • KBRC: 0.50
    • CNE: 0.50
  • Cost: Free
  • Release: Jun 15, 2022
  • Expires: Jun 14, 2025
  • Estimated Time to Complete:
    30 Minutes
  • Average User Rating:
    ( Ratings)

Faculty

 This activity has 5 faculty members associated with it.
Click Here to View All
Ellen J.  Hahn Ellen J. Hahn, PhD, RN, FAAN
Professor and Marcia A. Dake Endowed Professor
University of Kentucky College of Nursing

Director, BREATHE
Facilitator, UK Markey Cancer Center, Lung Cancer Translational Research Group

Chasity Harney Chasity Harney, MA
Radon Cancer Survivor
Covington, Kentucky

Kyle Kuykendall Kyle Kuykendall, MS
Radon Program Coordinator
BREATHE, UK College of Nursing
Lexington, Kentucky

Gloria Linnertz Gloria Linnertz
Director/Founder
Radon Activist
Citizens for Radioactive Radon Reduction
Waterloo, Illinois

Timothy W.  Mullett Timothy W. Mullett, MD, MBA, FACS
Professor, Division of Cardiothoracic Surgery
University of Kentucky College of Medicine
Medical Director, Network Operations
UK Markey Cancer Center
Lexington, Kentucky
Chair, Commission on Cancer
American College of Surgeons

Needs Statement

Radon is the leading cause of lung cancer in those who have never smoked and the second leading cause of lung cancer after smoking.

Module 3 addresses radon testing, radon mitigation, radon-resistant new construction, and the role of healthcare providers.

Target Audience

Physicians, Physician Assistants, Nurse Practitioners, Nurses, Respiratory Therapists, Lung Cancer Screening Providers, Counselors, Social Workers, Certified Health Educators, Real Estate Agents, Radon Awareness Advocates and Educators.

Objectives

Upon completion of this activity, participants will be able to:
1. Describe the recommendations for home radon testing.
2. Describe the process of and recommendations for home radon mitigation.
3. Discuss the role of healthcare providers in discussing home radon testing and mitigation with patients.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

IPE Competencies

  • Roles/ Responsibilities
  • Interprofessional Communication

Other
UK Healthcare CECentral certifies this activity for 0.50 hours of participation.

CPHCE
University of Kentucky College of Public Health certifies that this educational activity was designated for 0.50 hours of Public Health Continuing Education (CPHCE) credit. This course is approved for continuing education by the University of Kentucky College of Public Health. ()

CHES
Sponsored by Department of Public Health, Western Kentucky University, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 0.50 total Category I continuing education contact hours. Maximum advanced-level continuing education contact hours available are 0. 0.50 Continuing Competency credits are available. Provider ID# 61039

KBRC
This program has been reviewed and approved by the Kentucky Board of Respiratory Care.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Tim Mullett, MD, faculty for this educational event, has stock with OncoLens. 

All of the relevant financial relationships listed for these individuals have been mitigated.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with University of Kentucky College of Nursing and BREATHE.

The activity was supported by KY Department of Public Health.